Pipeline

Constantly growing pipeline of product opportunities

EVT Innovate develops drug discovery programmes and assets, both internally or through academic collaborations. Evotec seeks to partner these into collaborations in return for upfront payments, ongoing research payments and significant financial upside through milestones and royalties.

 

Pipeline of product opportunities (including EVT Execute programmes)

Programme
Therapeutic area/Indication
Partner
Status
EVT201
CNS - Insomnia
Jingxin
Phase II
BAY1817080
Chronic cough
Bayer
Phase II
ND
Chronic cough
Bayer
Phase II 
CT7001
Oncology
Carrick
Phase II
EVT401
Immunology & Inflammation
CONBA Group
Phase I
ND
Women`s health - Endometriosis
Bayer
Phase I
ND
Women`s health - Endometriosis
Bayer
Phase I
ND
Women`s health - Endometriosis
Bayer
Phase I
ND
Respiratory
Boehringer Ingelheim
Phase I
ND
Oncology
Boehringer Ingelheim/Xynomic Pharmaceuticals
Phase I
ND
CNS - Pain
Novartis
Pre-clinical
Various
Women`s health - Endometriosis
Bayer
Pre-clinical
ND
Immunology & Inflammation
Topas Therapeutics
Pre-clinical
ND
Pain
Boehringer Ingelheim
Pre-clinical
EVT801
Oncology
Sanofi
Pre-clinical
TargetImmuniT
Oncology - Immunotherapy
Sanofi/Apeiron
Pre-clinical
ND
Oncology
Exscientia
Pre-clinical + several discovery programmes
ND
Fibrosis
Galapagos
Pre-clinical
Various
Anti-infectives
>5 programmes
Pre-clinical
Various
CNS, Metabolic, Pain & Inflammation
>10 further programmes
Pre-clinical
Various
Nephrology
Bayer
Discovery
Various
Immunology & Inflammation
UCB
Discovery
Various
Neurodegeneration
Celgene
Discovery
Various
Oncology - solid tumours
Celgene
Discovery
Various
Immunology & Inflammation - Tissue Fibrosis
Pfizer
Discovery
Various
Metabolic - Diabetes
Sanofi
Discovery
TargetPicV
Antiviral
Bayer/Haplogen
Discovery
ND
Dermatological diseases
Almirall
Discovery
ND
Oncology
Breakpoint Therapeutics
Discovery
ND
Anti-infectives
Forge Therapeutics
Discovery
ND
FSHD
Facio Therapies
Discovery
INDY inhibitor
Metabolic
Eternygen
Discovery
ND
Fibrotic disease
Fibrocor/Galapagos
Discovery
Various
Various

LAB282 / LAB150 / LAB591 / LAB031 / LAB10x

Discovery
Various
Anti-infectives
>5 programmes
Discovery
Various
Internal: Oncology, CNS, Metabolic, Pain & Inflammtion, Immunology and Anti-invectives
>40 further programmes
Discovery
Programme EVT201
Therapeutic area/Indication CNS - Insomnia
Partner Jingxin
Status Phase II
Programme BAY1817080
Therapeutic area/Indication Chronic cough
Partner Bayer
Status Phase II
Programme ND
Therapeutic area/Indication Chronic cough
Partner Bayer
Status Phase II 
Programme CT7001
Therapeutic area/Indication Oncology
Partner Carrick
Status Phase II
Programme EVT401
Therapeutic area/Indication Immunology & Inflammation
Partner CONBA Group
Status Phase I
Programme ND
Therapeutic area/Indication Women`s health - Endometriosis
Partner Bayer
Status Phase I
Programme ND
Therapeutic area/Indication Women`s health - Endometriosis
Partner Bayer
Status Phase I
Programme ND
Therapeutic area/Indication Women`s health - Endometriosis
Partner Bayer
Status Phase I
Programme ND
Therapeutic area/Indication Respiratory
Partner Boehringer Ingelheim
Status Phase I
Programme ND
Therapeutic area/Indication Oncology
Partner Boehringer Ingelheim/Xynomic Pharmaceuticals
Status Phase I
Programme ND
Therapeutic area/Indication CNS - Pain
Partner Novartis
Status Pre-clinical
Programme Various
Therapeutic area/Indication Women`s health - Endometriosis
Partner Bayer
Status Pre-clinical
Programme ND
Therapeutic area/Indication Immunology & Inflammation
Partner Topas Therapeutics
Status Pre-clinical
Programme ND
Therapeutic area/Indication Pain
Partner Boehringer Ingelheim
Status Pre-clinical
Programme EVT801
Therapeutic area/Indication Oncology
Partner Sanofi
Status Pre-clinical
Programme TargetImmuniT
Therapeutic area/Indication Oncology - Immunotherapy
Partner Sanofi/Apeiron
Status Pre-clinical
Programme ND
Therapeutic area/Indication Oncology
Partner Exscientia
Status Pre-clinical + several discovery programmes
Programme ND
Therapeutic area/Indication Fibrosis
Partner Galapagos
Status Pre-clinical
Programme Various
Therapeutic area/Indication Anti-infectives
Partner >5 programmes
Status Pre-clinical
Programme Various
Therapeutic area/Indication CNS, Metabolic, Pain & Inflammation
Partner >10 further programmes
Status Pre-clinical
Programme Various
Therapeutic area/Indication Nephrology
Partner Bayer
Status Discovery
Programme Various
Therapeutic area/Indication Immunology & Inflammation
Partner UCB
Status Discovery
Programme Various
Therapeutic area/Indication Neurodegeneration
Partner Celgene
Status Discovery
Programme Various
Therapeutic area/Indication Oncology - solid tumours
Partner Celgene
Status Discovery
Programme Various
Therapeutic area/Indication Immunology & Inflammation - Tissue Fibrosis
Partner Pfizer
Status Discovery
Programme Various
Therapeutic area/Indication Metabolic - Diabetes
Partner Sanofi
Status Discovery
Programme TargetPicV
Therapeutic area/Indication Antiviral
Partner Bayer/Haplogen
Status Discovery
Programme ND
Therapeutic area/Indication Dermatological diseases
Partner Almirall
Status Discovery
Programme ND
Therapeutic area/Indication Oncology
Partner Breakpoint Therapeutics
Status Discovery
Programme ND
Therapeutic area/Indication Anti-infectives
Partner Forge Therapeutics
Status Discovery
Programme ND
Therapeutic area/Indication FSHD
Partner Facio Therapies
Status Discovery
Programme INDY inhibitor
Therapeutic area/Indication Metabolic
Partner Eternygen
Status Discovery
Programme ND
Therapeutic area/Indication Fibrotic disease
Partner Fibrocor/Galapagos
Status Discovery
Programme Various
Therapeutic area/Indication Various
Partner

LAB282 / LAB150 / LAB591 / LAB031 / LAB10x

Status Discovery
Programme Various
Therapeutic area/Indication Anti-infectives
Partner >5 programmes
Status Discovery
Programme Various
Therapeutic area/Indication Internal: Oncology, CNS, Metabolic, Pain & Inflammtion, Immunology and Anti-invectives
Partner >40 further programmes
Status Discovery

Contact us

Evotec

Business Development

T +44.(0)1235.86 15 61 F +44.(0)1235.86 31 39 vCard
TOP